Role of Amyloid-β and Tau Proteins in Alzheimer’s Disease: Confuting the Amyloid Cascade
Open accessThe DOI matches its Crossref record; 223 of the 223 references it cites were found in a registry or an index.
Abstract
The "Amyloid Cascade Hypothesis" has dominated the Alzheimer's disease (AD) field in the last 25 years. It posits that the increase of amyloid-β (Aβ) is the key event in AD that triggers tau pathology followed by neuronal death and eventually, the disease. However, therapeutic approaches aimed at decreasing Aβ levels have so far failed, and tau-based clinical trials have not yet produced positive findings. This begs the question of whether the hypothesis is correct. Here we have examined literature on the role of Aβ and tau in synaptic dysfunction, memory loss, and seeding and spreading of AD, highlighting important parallelisms between the two proteins in all of these phenomena. We discuss novel findings showing binding of both Aβ and tau oligomers to amyloid-β protein precursor (AβPP), and the requirement for the presence of this protein for both Aβ and tau to enter neurons and induce abnormal synaptic function and memory. Most importantly, we propose a novel view of AD pathogenesis in which extracellular oligomers of Aβ and tau act in parallel and upstream of AβPP. Such a view will call for a reconsideration of therapeutic approaches directed against Aβ and tau, paving the way to an increased interest toward AβPP, both for understanding the pathogenesis of the disease and elaborating new therapeutic strategies.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“TRx0237 (21, LMTX) is a tau aggregation inhibitor.465”
From Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies. (2024) · cites this paper as [465]
Citations
Cites
Neuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123 · cited 1×
“Also, tau pathology is likely to begin in EC then move to the hippocampus, and ultimately invading the cortex, following an overlapping path existing among functionally connected areas [55, 157, 158, 177].”
The Amyloid Hypothesis of Alzheimer’s Disease: Progress and Problems on the Road to Therapeutics
Hardy, J., & Selkoe, D. J. (2002) · Science · doi:10.1126/science.1072994 · Cited by 13,864 · cited 3×
“Unfortunately, while the “Oligomer Hypothesis” is still a matter of investigation, and data are being gathered to test the grounds of its premises, the clinical failure of most of the anti-A (cid:2) drugs has strongly destabilized this concept.”
Amyloid oligomers exacerbate tau pathology in a mouse model of tauopathy
Selenica, M.-L. B., Brownlow, M., Jimenez, J. P., Lee, D. C., Pena, G., Dickey, C. A., Gordon, M. N., & Morgan, D. (2013) · Neurodegenerative Diseases · doi:10.1159/000337230 · Cited by 10,359
Alzheimer's disease: the amyloid cascade hypothesis
Hardy, J. A., & Higgins, G. A. (1992) · Science · doi:10.1126/science.1566067 · Cited by 7,484
Glenner, G. G., & Wong, C. W. (1984) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(84)80190-4 · Cited by 5,404
Alzheimer's Disease Is a Synaptic Failure
Selkoe, D. J. (2002) · Science · doi:10.1126/science.1074069 · Cited by 4,420
Terry, R. D., Masliah, E., Salmon, D. P., Butters, N., DeTeresa, R., Hill, R., Hansen, L. A., & Katzman, R. (1991) · Annals of Neurology · doi:10.1002/ana.410300410 · Cited by 4,397 · cited 1×
“Second, we know since the 1990 s that there is no correlation between A (cid:2) deposition and clinical degree of dementia among affected individuals [25–28], and plaques might occur in the brains of individuals with no sign of dementia [27, 29, 30].”
Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis
Kayed, R., Head, E., Thompson, J. L., McIntire, T. M., Milton, S. C., Cotman, C. W., & Glabe, C. G. (2003) · Science · doi:10.1126/science.1079469 · Cited by 4,064 · cited 1×
“This was predicted by a study showing that all of the soluble oligomers tested including β-synuclein, islet amyloid polypeptide, polyglutamine, lysozyme, human insulin, and prion peptide 106–126, display a common conformation-dependent structure that is unique to soluble oligomers [193], By now, a variety of studies h…”
BackgroundClinical and biomarker changes in dominantly inherited Alzheimer's disease
Bateman, R. J., Xiong, C., Benzinger, T. L. S., Fagan, A. M., Goate, A., Fox, N. C., Marcus, D. S., Cairns, N. J., Xie, X., Blazey, T. M., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1202753 · Cited by 3,814 · cited 1×
“This temporal sequence derives from studies in patients with FAD, where the genetic-driven increase of Aβ is followed by NFT accumulation [194], whereas the increase of tau, as in tauopathies, is not associated with Aβ deposition.”
BackgroundShankar, G. M., Li, S., Mehta, T. H., Garcia-Munoz, A., Shepardson, N. E., Smith, I., Brett, F. M., Farrell, M. A., Rowan, M. J., Lemere, C. A., et al. (2008) · Nature Medicine · doi:10.1038/nm1782 · Cited by 3,685
Cited by
Items 201–300 of 314
Morita, S., Ren, Z., Fan, H., & Hua, D. H. (2023) · ChemistrySelect · doi:10.1002/slct.202301435 · Cited by 3
Cai, H., Du, R., Yang, K., Li, W., & Wang, Z. (2023) · Current Neuropharmacology · doi:10.2174/1570159x21666230807144750 · Cited by 4
“Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by the deposition of amyloid-β plaques and hyperphosphorylated tau tangles [1].”
BackgroundPuzzo, D. (2024) · Journal of Alzheimer s Disease · doi:10.3233/jad-240406 · Cited by 3
Self-citationBrain tissue electrical conductivity as a promising biomarker for dementia assessment using MRI
Chu, J., Yao, J., Li, Z., Li, J., Zhang, Y., Liu, C., He, H., Li, B., & Wei, H. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70270 · Cited by 5
18F-THK 5351 and 11C-PiB PET of the Thai normal brain template.
Chotipanich, C., Kongthai, S., Kunawudhi, A., Promteangtrong, C., & Jantarato, A. (2021) · Europe PMC (PubMed Central) · doi:10.22038/aojnmb.2020.49623.1338 · Cited by 4
Heat shock protein and Alzheimer’s disease: an updated systematic review
Raza, H., Ali, A., Kumar, A., Adnan, F., Shah, S. A. W., Ghazanfar, S., Roshan, F. N. U., Shamim, Z., Opare, A. D., & Tanveer, F. S. (2025) · Annals of Medicine and Surgery · doi:10.1097/ms9.0000000000002887 · Cited by 2
“The brains of individuals diagnosed with AD exhibit the presence of senile plaques, characterized by the accumulation of insoluble A β peptides consisting of a sequence ranging from 38 to 42 amino acids [ 8 ] .”
Elbatrawy, A. A., Ademoye, T. A., Alnakhala, H., Tripathi, A., Zhu, X., Plascencia‐Villa, G., Perry, G. L., Dettmer, U., & Fortin, J. S. (2025) · ACS Omega · doi:10.1021/acsomega.4c08385 · Cited by 3
Machine Learning for Early Prediction of Cognitive Decline in Alzheimer's Disease
Palma, L. D., Nisio, A. D., Lanzolla, A. M. L., Matarrese, P., Pich, E. M., & Attivissimo, F. (2025) · IEEE International Symposium on Medical Measurements and Applications (MeMeA) · doi:10.1109/memea65319.2025.11068006 · Cited by 4
“The exact cause of Alzheimer remains unclear, but it is thought to involve the accumulation of abnormal protein deposits, such as amyloid plaques and tau neurofibrillary tangles [1]-[2].”
Prediction of mild cognitive impairment progression using time-sensitive multimodal biomarkers
Gallego-Rudolf, J., Wiesman, A. I., Yakoub, Y., Zetterberg, H., Blennow, K., Baillet, S., & Villeneuve, S. (2026) · Science Advances · doi:10.1126/sciadv.aee2305 · Cited by 3
“A β and tau begin accumulating many years before cognitive symptoms emerge ( 5 , 11 ), initiating downstream pathological processes that ultimately lead to synaptic dysfunction, neurodegeneration, and progressive cognitive decline ( 12 – 15 ).”
Wu, G., Chen, Y., Yao, Y., Huang, W., & Wu, K. (2025) · Pesticide Biochemistry and Physiology · doi:10.1016/j.pestbp.2025.106821 · Cited by 4
Nath, R., Bhattacharjee, S., Ashique, S., Panda, S., Maiti, N. J., Akhtar, M. J., Debnath, I., Hussain, M. S., Debnath, B., Attar, J. R., et al. (2025) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2025.144837 · Cited by 3
Elbermawy, Y., El-Desouky, S., Arafa, R. K., Elfarrash, S., & Bassiouny, A. R. (2025) · Molecular Neurobiology · doi:10.1007/s12035-025-05534-9 · Cited by 5
“Its multifactorial pathology involves progressive cognitive decline and neuropathological hallmarks including extracellular β-amyloid (Aβ) plaques and intracellular neurofibrillary tangles formed by hyperphosphorylated tau protein [2].”
Alrouji, M., Alshammari, M. S., Alhajlah, S., Syed, T., Ashraf, G. M., Dinislam, K., Shahwan, M. J., & Shamsi, A. (2026) · Engineering · doi:10.1016/j.eng.2025.12.030 · Cited by 5
Lian, Q., Sun, Q., Han, X., Ma, H., Guo, J., Wen, B., Wang, P. Y., Li, R., Shan, A., Cui, T., et al. (2026) · Journal of Clinical and Experimental Neuropsychology · doi:10.1080/13803395.2026.2671206 · Cited by 3
“…of tau protein at the Ser217 site is a landmark event in the formation of neurofibrillary tangles in neurons during the early stage of AD, and the degree of phosphorylation is spatiotemporally correlated with Aβ deposition (Gulisano et al., 2018; Metaxas & Kempf, 2016; Rawat et al., 2022).”
Poulin, M., & Golime, R. (2026) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.5c00771 · Cited by 3
Molecular etiopathogenesis of neurodegenerative diseases
Divya, D., Thekkekkara, D., Sai, T. E., Ramakrishna, D., Manjula, S. N., & Goswami, S. K. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-28822-7.00002-7 · Cited by 3
Doering, S., McKay, N. S., Jana, N., Dombrowski, K., McCullough, A. A., Millar, P. R., Hobbs, D. A., Agrawal, R., Flores, S. E., Llibre‐Guerra, J. J., et al. (2024) · Imaging Neuroscience · doi:10.1162/imag_a_00405 · Cited by 5
“This is consistent with several studies demonstrating the onset of tau pathological accumulation after widespread amyloid plaque accumulation but prior to clinical diagnosis observed in preclinical AD (Bloom, 2014; Gulisano et al., 2018).”
A comprehensive analysis of MAPT-related genetic risk in Alzheimer’s disease
Wang, S., Luo, G., Ding, X., Sun, G., Zhang, M., Dong, J., Xu, H. M., Lu, J., Li, Z., Ning, B., et al. (2025) · IBRO Neuroscience Reports · doi:10.1016/j.ibneur.2025.01.017 · Cited by 3
Bhat, P., Selvi, V. G., Dheeraj, V., & Sailaja, Y. (2025) · International Conference on Advances in Modern Age Technologies for Health and Engineering Science (AMATHE) · doi:10.1109/amathe65477.2025.11081213 · Cited by 2
Biological macromolecules acting on central nervous system
Pal, D., & Raj, K. (2021) · Elsevier eBooks · doi:10.1016/b978-0-323-85759-8.00009-9 · Cited by 2
Arévalo, L. A., Antonova, O., O’Brien, S. A., Singh, G., & Seifert, A. (2022) · Journal of Physics Conference Series · doi:10.1088/1742-6596/2407/1/012026 · Cited by 3
Piezo channels as molecular gatekeepers: A review of their involvement in alzheimer\'s disease
Prajapati, B. G., Raghani, N. R., & Chorawala, M. R. (2023) · IP International Journal of Comprehensive and Advanced Pharmacology · doi:10.18231/j.ijcaap.2023.033 · Cited by 1
Rahmanto, I., Cahyono, M. B. A., Khatimah, H., Nugraningrum, R., Putri, P. S. G., Sahiruddin, N. Z., Rahmaniah, N., & Romadhon, P. Z. (2024) · Qanun Medika - Medical Journal Faculty of Medicine Muhammadiyah Surabaya · doi:10.30651/jqm.v8i01.16054 · Cited by 2
Improved Expression of Aggregation-Prone Tau Proteins Using a Spidroin-Derived Solubility Tag
Muwonge, K., Yaman, B., Mészáros, A., Russo, G., Volkov, A. N., & Tompa, P. (2024) · Separations · doi:10.3390/separations11070198 · Cited by 2
“It houses two crucial hydrophobic hexapeptide motifs, which are essential for both the seeding and propagation of Tau aggregates [64,65].”
BackgroundRecent updates on immunotherapy in neurodegenerative diseases
Salunkhe, J., & Ugale, R. R. (2024) · Brain Research · doi:10.1016/j.brainres.2024.149205 · Cited by 2
Progress of Chinese Medicine in Regulating Microglial Polarization against Alzheimer’s Disease
Yang, F., Gao, W., Wang, J. Z., Li, X., & Li, H. (2024) · The American Journal of Chinese Medicine · doi:10.1142/s0192415x24500873 · Cited by 2
A Tool Kit to Model Neurodegenerative Disease in Drosophila melanogaster
Mainali, S., Majlish, A. N. K., Lee, Y. R., Lee, H., Iyengar, A. S. R., & Chtarbanova, S. (2024) · Neuromethods · doi:10.1007/978-1-0716-4232-0_12 · Cited by 1
Makgato, K. S., Gololo, S. S., MNCUBE, S. C., Motlhatlego, K. E., & Thibane, V. S. (2025) · South African Journal of Botany · doi:10.1016/j.sajb.2025.02.030 · Cited by 2
Salmon, P., & Soriano, J. (2025) · Lecture notes in computer science · doi:10.1007/978-981-96-3294-7_28 · Cited by 1
A comparison of biomarker modalities for predicting disease progression in dementia patients
Early, S., Wilms, M., & Forkert, N. D. (2025) · SPIE Medical Imaging: Imaging Informatics for Healthcare, Research, and Applications · doi:10.1117/12.3047109 · Cited by 1
“Additionally, these biomarkers have been suggested to be able to detect early disease changes prior to any structural abnormalities appearing on an MRI 36 .”
Mainali, N., Balasubramaniam, M., Pahal, S., Griffin, W. S. T., Reis, R. J. S., & Ayyadevara, S. (2025) · Basic Research in Cardiology · doi:10.1007/s00395-025-01109-w · Cited by 2
“Aβ and tau accumulate in the brain and can be detected in serum or plasma as well as cerebrospinal fluid [25, 36, 98].”
Ryu, T., Kim, S., Thuraisamy, T., Shin, J., Jang, Y., Kam, T., & Na, C. H. (2025) · Advanced Science · doi:10.1002/advs.202409318 · Cited by 2
Peyvand, P., Allami, P., & Rezaei, N. (2025) · Reviews in the Neurosciences · doi:10.1515/revneuro-2025-0025 · Cited by 1
Neurodegenerative Disorder: An Overview
Verma, M., Shukla, S., Shrivastava, S., & Puranik, N. (2025) · Springer eBooks · doi:10.1007/978-981-96-6202-9_1 · Cited by 2
Protein misfolding and neurodegeneration: Mechanisms, implications, and therapeutic strategies
Shah, A., Karthikeyan, T., Hashem, S., Kumar, R., Bhat, A. A., & Macha, M. A. (2025) · Advances in protein chemistry and structural biology · doi:10.1016/bs.apcsb.2025.08.012 · Cited by 2
Christodoulou, R. C., Vamvouras, G., Sarquis, M. D., Petrou, V., Papageorgiou, P. S., Rivera, L., Morales, C., Rivera, G., Vassiliou, E. K., Solomou, E. E., et al. (2025) · Biomedicines · doi:10.3390/biomedicines13112632 · Cited by 2
“On top of that, a high amyloid burden enhances tau hyperphosphorylation, misfolding, and aggregation into neurofibrillary tangles, resulting in high tau levels, leading to neuronal death and cognitive decline [34].”
Mujtaba, M., Shafiq, M. I., Ismail, H., Hameed, M., Al-Otaibi, J. S., & Khan, H. (2025) · Letters in Drug Design & Discovery · doi:10.1016/j.lddd.2025.100201 · Cited by 2
Qi, L., Lin, L., Zheng, J., Liu, X., Liu, X., Chen, Z., & Liu, L. (2025) · The Journals of Gerontology Series A · doi:10.1093/gerona/glaf265 · Cited by 1
Understanding molecular role of lipids for Alzheimer’s disease
Upadhyay, R., Velmurugan, G., Krishnan, D., Sivasamy, R., Sevanan, M., & Chinnathambi, S. (2025) · Advances in protein chemistry and structural biology · doi:10.1016/bs.apcsb.2025.10.011 · Cited by 1
Massand, A., Rai, R., Rai, A. R., & Joy, T. (2026) · 3 Biotech · doi:10.1007/s13205-025-04647-1 · Cited by 1
“In Alzheimer’s disease insoluble aggregation of amyloid beta-peptide and Tau protein in neurofibrillary tangles are the common features (Gulisano et al. 2018; Nam et al. 2025).”
Xia, K., Relvas, J. B., Zheng, X., & Hao, H. (2025) · Targetome · doi:10.48130/targetome-0025-0007 · Cited by 1
Cognitive Decline and Neurodegenerative Markers in Psoriasis: The Role of APOE4 and Beta-Amyloid
Sabry, H. H., Kadhum, B. Q., Abdulmohsin, G. N., El-Ghaffar, A. O. A., Mahmoud, M. M., & Shams, G. M. (2026) · Dermatology Practical & Conceptual · doi:10.5826/dpc.1601a5957 · Cited by 1
“Research indicates that accumulation of A β plaques and tau protein abnormalities significantly heighten cognitive decline risk and dementia [11,12].”
Wang, R., Feng, Y., Zhou, Z., Jiang, J., Zhang, R., Zou, W., Yang, H., Lv, W., & Shen, Y. (2026) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2026.1748418 · Cited by 7
“…research has demonstrated that the accumulation of A β oligomers and plaques triggers downstream pathological processes, including tau protein hyperphosphorylation, neurofibrillary tangle formation, and synaptic dysfunction (Gulisano et al., 2018; Rajmohan and Reddy, 2017; Wu et al., 2021).”
Artificial intelligence and multiomics integration for Parkinson’s disease drug development
Lee, S., Kim, J., Jung, H., Kim, D., Cho, E., Kim, Y.-J., Ji, Y. R., Go, Y., Song, P., Oh, Y., et al. (2026) · Molecules and Cells · doi:10.1016/j.mocell.2026.100343 · Cited by 2
Pyo, B.-J., Lee, J., Lee, H. A., Won, K. S., & Kim, H. W. (2026) · Topics in Clinical Nutrition · doi:10.1097/tin.0000000000000416 · Cited by 1
Hirota, Y., Yamamoto, J., Takatori, S., Sakakibara, Y., Takei, K., 佐治多美子, Sekiya, M., Tomita, T., & Iijima, K. (2026) · Molecular Neurodegeneration Advances · doi:10.1186/s44477-026-00032-1 · Cited by 1
“The neuropathological hallmarks of AD include extracellular deposition of amyloid-β peptides (Aβ) and intracellular aggregation of neurofibrillary tangles (NFTs) composed of hyperphosphorylated tau protein [4–6].”
The mitochondria-synapse axis in Alzheimer’s disease: Lost coordination in early stages
Sharma, P., Kaur, N., Vasal, N., Solanki, K., & Sunkaria, A. (2026) · Ageing Research Reviews · doi:10.1016/j.arr.2026.103168 · Cited by 2
Shahadab, M., Saini, V., Singh, S., Prakash, O., Sachin, K., Pandey, R. K., Meena, A. K., & Jha, H. C. (2026) · Stem Cell Reviews and Reports · doi:10.1007/s12015-026-11147-z · Cited by 1
“According to the amyloid cascade hypothesis, aberrant Aβ aggregation triggers a pathogenic cascade that leads to oxidative stress, Tau hyperphosphorylation, and neuroinflammation, ulti - mately resulting in neuronal death [21 ].”
Gautam, A. S., & Singh, R. K. (2026) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-026-10294-x · Cited by 1
“…of Aβ 1−42 in the brain and formation of neurofi - brillary tangles are the major hallmark biomarkers of the disease (Sadigh-Eteghad et al. 2015; Gulisano et al. 2018; Rawat et al. 2022 ), the neuroinflammation during disease progression also accounts for major pathological features of the…”
Froes, B. R., Pina, J. G., Alves, M. D. M., Mançano, A. S. F., Cardoso, F. C., & Sciani, J. M. (2026) · Pharmaceutics · doi:10.3390/pharmaceutics18060696 · Cited by 1
“This peptide can accumulate either extracellularly or intracellularly in neurons, where its soluble oligomers exert early neurotoxic effects [1,4].”
Upadhyay, R., Kar, S., & Sevanan, M. (2026) · Frontiers in Chemical Biology · doi:10.3389/fchbi.2026.1836070 · Cited by 2
Efficacy of antioxidants as a therapy for Alzheimer's disease: a meta-analysis
Li, J., Chen, B., Jiang, J., Feng, Y., Zhang, R., Li, D. M., Wang, R., Long, Z., Ge, L., Guo, Y., et al. (2026) · Frontiers in Nutrition · doi:10.3389/fnut.2026.1878597 · Cited by 2
Buzoianu, A. D., Sharma, A., Muresanu, D. F., Feng, L., Huang, H., Chen, L., Tian, Z. R., Nozari, A., Lafuente, J. V., Wiklund, L., et al. (2023) · Advances in neurobiology · doi:10.1007/978-3-031-32997-5_2 · Cited by 2
Biosensors for detection of Alzheimer’s disease: a review
Tewari, M. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-19129-9.00005-4 · Cited by 1
Safety and effectiveness of Donepezil and Memantine in Alzheimer's Disease
Ghosh, A. (2025) · International Journal of Pharmaceutical Sciences and Drug Research · doi:10.25004/ijpsdr.2025.170310
Moallemian, S., Salmon, É., Bahri, M. A., Beliy, N., Delhaye, E., Balteau, E., Phillips, C. L. M., & Bastin, C. (2023) · medRxiv · doi:10.1101/2023.04.14.23288516 · Cited by 1
“These pathological processes include a progressive accumulation of amyloid-beta plaques and tau neurofibrillary tangles (NFT), in addition to synaptic and neuronal loss (Gulisano et al., 2018; Jack et al., 2013; Spillantini and Goedert, 2013; Tan et al., 2014; Yin et al., 2021).”
BackgroundDiorio, T. C., Abderezaei, J., Nauman, E. A., Kurt, M., Tong, Y., & Rayz, V. L. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.08.01.606246 · Cited by 1
Wu, F., Steadman, C., Argent, L. P., Jamieson, B. G., Vellarikkal, S. K., Tamburino, A. M., Khalil, I. G., Peterson, V. M., Kennedy, M. E., Mathew, R. S., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.09.12.675888 · Cited by 3
“This distinction is particularly relevant for neurodegenerative diseases (e.g., AD), where molecular hallmarks may not map directly onto behavioral or physiological outcomes 57,58,85 .”
Tropea, M. R., Puma, D. D. L., Melone, M., Gulisano, W., Arancio, O., Grassi, C., Conti, F., & Puzzo, D. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.01.05.425382
“On the other hand, the Aβ Hypothesis (Hardy and Allsop, 1991) posits that the increase and accumulation of Aβ represent the primum movens in AD pathophysiology, responsible of synaptic dysfunction triggering downstream events leading to dementia [reviewed in (Gulisano et al., 2018a)].”
BackgroundMethodSelf-citationZampar, S. (2021) · eDiss (Georg-August-Universität Göttingen) · doi:10.53846/goediss-9004
A Preliminary Study on the Mechanism of Alcohol Abuse in Alzheimer’s Disease
徐, 加. (2023) · Open Journal of Natural Science · doi:10.12677/ojns.2023.112017
Limb Speed Perception Accuracy in Neurodegenerative Disease
Brandmeir, C. L. (2024) · The Research Repository @ WVU (West Virginia University) · doi:10.33915/etd.12362 · Cited by 1
Molecular Modeling Insights on the Pharmaceuticals and Hypotheses of Alzheimer’s Disease
de Castro, A. A., Silva, H. F., Garcia, M. V. F. P., Homem‐de‐Mello, P., & Ramalho, T. C. (2024) · Current Medicinal Chemistry · doi:10.2174/0109298673318143240823064403 · Cited by 1
Identifying Alzheimer’s disease-associated genes using PhenoGeneRankerPreprint
Rahman, M. T., Saeed, F., Bozdag, S., & Initiative, A. D. N. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.11.12.623269
Ejaz, S., Sternburg, J. O., Rezvani, K. S., Ahammed, M. S., Giri, S., Liu, J., Wang, H., & Wang, X. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.03.24.645024
“Growing evidence suggests that insufficient clearance of misfolded proteins (e.g., tau and amyloid beta) plays an important role in most cases of AD (10).”
Efficient regularized estimation of graphical proportional hazards model with interval-censored data
Lu, H., Wang, Y., Bing, H., Wang, S., & Li, N. (2025) · Computational Statistics & Data Analysis · doi:10.1016/j.csda.2025.108178
Докукина, Т. В., Голубева, Т. С., Мисюк, Н. Н., Гамова, А. В., Асташонок, А. Н., & Байкова, А. В. (2025) · Рецепт · doi:10.34883/pi.2025.28.2.002
Lewandowska, J., Majewski, J., & Roszek, K. (2025) · Brain Sciences · doi:10.3390/brainsci15060570
“In both rat cerebral cortex cells and microglia, A β 1–42 causes the release of ATP outside the cells via one of two mechanisms: lytic or nonlytic [29,55].”
Overview of Bioactive Compounds for Neurodegenerative Disorders
Tripathi, S. M., Mishra, S. K., Malviya, R., & Ojha, S. (2025) · BENTHAM SCIENCE PUBLISHERS eBooks · doi:10.2174/9789815324846125010003
Hasan, U., Jain, H., & Ali, R. (2025) · Current Drug Targets · doi:10.2174/0113894501388678250618070927
β-Amyloid Pathways in Alzheimer's Disease: Mechanisms and Therapeutic Targets
Bansal, S., Yadav, M., Bisht, P., Bansal, D., Tushir, S., & Rathore, D. (2025) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/0118715273382447250526062100 · Cited by 1
Lin, K., Yang, J., Li, H., Zhong, S., Zeng, X., Hu, W., Cheng, L., & Xu, S. (2025) · Research Square · doi:10.21203/rs.3.rs-7280838/v1
Li, Y., & Liu, J. (2025) · Advances in Alzheimer s Disease · doi:10.4236/aad.2025.143006
A metabolite extracted from Escherichia coli suppresses tau aggregation
Srinivasan, M., Patel, A., Patel, T., Moore, J., Gomez‐Cardona, E., Yarahmady, A., Sykes, B. D., Julien, O., & Mok, S. (2026) · Biochemical Journal · doi:10.1042/bcj20260068
Antibodies targeting amyloid-β and Tau oligomers in Alzheimer’s disease
Chinnathambi, S., Rangappa, N., & Chandrashekar, M. (2025) · Advances in protein chemistry and structural biology · doi:10.1016/bs.apcsb.2025.10.002
Ling, R., Kuang, J., Zhang, H., Lin, Y. B., Jiang, J., Ge, R., & Yang, Y. (2025) · ICME International Conference on Complex Medical Engineering (CME) · doi:10.1109/cme67420.2025.11239061
“At the molecular level, abnormal protein aggregation and neurotransmitter imbalances play crucial roles[3-5].”
Ermilov, V. V., & Nesterova, A. (2025) · Russian Journal of Archive of Pathology · doi:10.17116/patol20258706161 · Cited by 1
Biosimilars: Antibody and nanobody-based therapeutic approaches towards protein misfolding diseases
Chinnathambi, S., & Rangappa, N. (2025) · Advances in protein chemistry and structural biology · doi:10.1016/bs.apcsb.2025.10.014
Ham, H. J., Park, S. S., Lee, Y. S., Kim, T. H., Son, D. J., Kim, J.-H., Lim, K., Park, H., Lee, H. J., Yun, J., et al. (2026) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2025.1728279
Sánchez-Puebla, L., López-Cuenca, I., Sánchez-Puebla, M. A., Granados, A., Ramírez, A., Lloréns, J., Saido, T., Saito, T., Nieto-Vaquero, C., Moro, M. A., et al. (2026) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2025.1712480
Bee Bread Shows Protective Effects in a Streptozotocin-Induced Alzheimer's Disease Rat Model
Acun, A. D., Afşar, E., & Kantar, D. (2026) · Bratislavské lekárske listy/Bratislava medical journal · doi:10.1007/s44411-026-00490-9
“Data from thousands of studies on the pathophysiology of AD to date identify Aβ and tau protein as key players [30].”
Badal, R., Kaur, B., Singh, H., Sharma, P., Yadav, P., Mahapatra, A., Ghildiyal, S., Patel, A. K., Kumar, L., Sharma, B., et al. (2026) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2026.111742
Alzate‐Correa, D., Stranan, J. P., Rincon‐Benavides, M. A., Mazo, N. A., Narváez-Pérez, L. F., Jaramillo-Garrido, S., Nguyen, T., Patel, R., Lawrence, W. R., Diaz‐Starokozheva, L., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.01.22.700900
Alzheimer's Disease Revisited: An Integrative Review of Modern Neurology and Ayurvedic Therapeutics
Modi, D., Dasar, D., Singh, N., & Shinde, K. (2026) · Journal of Natural Remedies · doi:10.18311/jnr/2026/50239 · Cited by 1
Cardenal, C. V., Mahfooz, K., Garcia‐Ratés, S., Hasan, S., & Greenfield, S. A. (2026) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2026.119125
Saha, P., & Chouhan, A. (2026) · Molecular Diversity · doi:10.1007/s11030-026-11507-4
Sirag, N., Elfadil, H., Ghabban, A. J., Alasiri, A. M., Alnasser, I. R., Bedaiwi, H. S., Alharbi, S. F., Almarwani, M. J., Aljohani, O. M., Hassan, H. M., et al. (2026) · The Keio Journal of Medicine · doi:10.2302/kjm.2025-0017-oa
Sharma, S., Sharma, U., Sethiya, N. K., & Singh, L. (2026) · Current Aging Science · doi:10.2174/0118746098373086251201095903 · Cited by 1
The Role of Presynaptic Cytomatrix Protein Bassoon (BSN) in Tau Pathology and Propagation
Oo, W. J., Sia, W. T., Lee, J. Y., Chen, C. H., Chang, W., & Chye, S. M. (2026) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/0118715273400895251129055504
D-sérine : un maillon central de la physiopathologie amyloïde ?
Ploux, E. (2022) · theses.fr (ABES) · doi:10.70675/e7b5bba0z9abcz4325zae71z841a60892f8b
Future perspectives: Toward universal early detection of chronic diseases
Hooshmandi, E. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-33263-0.00005-x
Elephant herding algorithm for the multiple sequence alignment problem
Ríos-Willars, E., Delabra-Salinas, M. M., & Carrillo-Gaona, R. E. (2026) · Evolutionary Intelligence · doi:10.1007/s12065-026-01197-0
“Let: ● The alignment is a list of n aligned sequences, each of length L . neurodegeneration, inflammation, and synaptic dys - function [ 31 – 32 ].”
Kim, D., Jeon, H. B., Shim, K.-S., Park, J. S., Yoon, J., Lee, J. H., Park, J.-H., Park, J.-H., Kim, J. H., Yoon, J., et al. (2026) · Biomaterials Research · doi:10.34133/bmr.0371
Curcumin as theranostics: imaging-guided therapeutics in oncology and neurodegenerative diseases
Yasir, M., Maurya, R. K., & Tripathi, A. S. (2026) · Frontiers in Nutrition · doi:10.3389/fnut.2026.1790555
“Extracellular A β oligomers can activate intracellular kinases, such as GSK-3 β , and inflammatory pathways that facilitate tau hyperphosphorylation (147).”
Lee, S., Choi, B. J., Park, M. H., Park, S., Kim, J., Jin, H. K., Shim, H., Jeon, J.-W., & Bae, J. (2026) · Journal of Alzheimer s Disease · doi:10.1177/13872877261458360
Ngo, J. C., Xu, Y., Olah, M., & Sher, F. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.06.30.735672
Tropea, M. R., Aceto, G., Trovato, R. C., Nicitra, E., Santuccio, N., Intili, G., D’Ascenzo, M., & Puzzo, D. (2026) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2026.1840697
“Extracellular field recordings were conducted on 400 µ m transverse hippocampal slices as described previously (Gulisano et al., 2019).”
Self-citationHernández, D. L. P., Sánchez, Á. A. L., & Juárez, R. G. (2026) · Casos y Revisiones de Salud · doi:10.22201/fesz.26831422e.2026.8.1.6
Singh, N., Guha, L., & Kumari, A. (2026) · Therapeutic Delivery · doi:10.1080/20415990.2026.2715878
Akhter, F., Akhter, A., Zhou, J., Xi, M., & Zhu, D. (2026) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2026.08.054
Metadata
- Authors
- Gulisano, W., Maugeri, D., Baltrons, M. A., Fà, M., Amato, A., Palmeri, A., D’Adamio, L., Grassi, C., Devanand, D. P., Honig, L. S., Puzzo, D., & Arancio, O.
- Affiliations
- University of Catania (IT)
- Taub Institute for Research on Alzheimer’s Disease and the Aging Brain, Columbia University, New York, NY, USA
- Columbia University (US)
- Università Cattolica del Sacro Cuore (IT)
- Department of Pharmacology, Physiology and Neuroscience, Rutgers University, Newark, NJ, USA
- Corresponding author
- Puzzo, Daniela
- Arancio, Ottavio
- ORCID
- Venue
- Journal of Alzheimer's Disease
- Publisher
- SAGE Publications
- Published
- 2018-06-12
- Volume
- 64
- Issue
- s1
- Pages
- S611-S631
- ISSN
- 1387-2877 (ISSN-L)
- 1875-8908
- PMC
- PMC8371153
- OpenAlex
- W2807540667
- Cited by
- 313
- References
- 223
- Citations by year
- 2026: 59 · 2025: 92 · 2024: 60 · 2023: 32 · 2022: 23 · 2021: 17 · 2020: 18 · 2019: 10 · 2018: 2
- FWCI
- 1.54
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Journal of Alzheimer s Disease (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Dipòsit Digital de Documents de la UAB (Universitat Autònoma de Barcelona) (submittedVersion, public-domain)
- Funders
- National Institute on Aging (R01AG049402, R01AG017761)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- Alzheimer's disease, amyloid-beta
- MeSH terms
- Alzheimer Disease, Animals, Humans, Signal Transduction, Amyloid beta-Peptides, tau Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.